Caris Life Sciences (NASDAQ:CAI) Price Target Lowered to $32.00 at BTIG Research

Caris Life Sciences (NASDAQ:CAI) had its target price reduced by investment analysts at BTIG Research from $38.00 to $32.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 61.29% from the stock’s previous close.

Several other research analysts have also weighed in on CAI. Wall Street Zen lowered Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Canaccord Genuity Group dropped their target price on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Friday, March 13th. Robert W. Baird upped their target price on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Jefferies Financial Group assumed coverage on Caris Life Sciences in a research report on Monday, April 13th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on Caris Life Sciences in a research report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Caris Life Sciences currently has an average rating of “Hold” and a consensus price target of $28.00.

Caris Life Sciences Trading Up 3.7%

Shares of Caris Life Sciences stock opened at $19.84 on Friday. The business has a 50-day simple moving average of $19.15. The stock has a market cap of $5.61 billion and a P/E ratio of -110.22. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85. Caris Life Sciences has a 1 year low of $16.28 and a 1 year high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to analyst estimates of $281.00 million. During the same period in the previous year, the company earned ($1.73) earnings per share. The business’s revenue for the quarter was up 125.4% on a year-over-year basis. On average, equities analysts forecast that Caris Life Sciences will post 0.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CAI. Global Retirement Partners LLC increased its holdings in shares of Caris Life Sciences by 99,900.0% during the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock valued at $27,000 after acquiring an additional 999 shares during the last quarter. Olistico Wealth LLC acquired a new position in shares of Caris Life Sciences during the 4th quarter valued at about $31,000. Fifth Third Bancorp acquired a new position in shares of Caris Life Sciences during the 1st quarter valued at about $31,000. Sterling Capital Management LLC increased its holdings in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Strs Ohio increased its holdings in shares of Caris Life Sciences by 301.3% during the 1st quarter. Strs Ohio now owns 2,179 shares of the company’s stock valued at $39,000 after acquiring an additional 1,636 shares during the last quarter.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.